MedPath

The REgistry of Very Early Estrogen and AnovuLation

Recruiting
Conditions
Hypothalamic Amenorrhea, Functional
Hypothalamic Amenorrhea
Functional Hypogonadotropic Hypogonadism
Interventions
Other: Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24)
Other: REVEAL Questionnaire
Registration Number
NCT06583408
Lead Sponsor
Mayo Clinic
Brief Summary

The purpose of this study is to to build a registry of women with early estrogen loss due to Functional Hypothalamic Amenorrhea (FHA) to understand the prevalence, racial and ethnic diversity of this condition.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
100000
Inclusion Criteria
  • 3 or more months of consecutive amenorrhea with a diagnosis of functional hypothalamic amenorrhea or screening hormones consistent with functional hypothalamic amenorrhea including but not limited to:

    • Estradiol: < 50pg/mL
    • LH: < 10 IU/mL
    • FSH: < 10 IU
    • Testosterone: 2 - 45 ng/dL
    • Free Testosterone: 0.1 - 6.4 pg/mL
    • FT4: 0.93 - 1.70 ng/dL
    • Prolactin: < 20 ng/mL
    • AMH: > 1 ng/mL
    • Urine or serum human chorionic gonadotropin: Negative
  • LH:FSH Ratio <1

  • No signs of male-like hair growth on the upper lip, chin, chest, abdomen, buttocks, or back

  • Does not have a diagnosis for secondary amenorrhea, including prolactinoma, PCOS, premature ovarian insufficiency, pituitary surgery, infection, or infarction

  • Premenopausal status determined by WISE criteria

  • Able to give informed consent

  • Able to read English

Read More
Exclusion Criteria
  • Parturition/lactating in the last 6-12 months
  • Lack of consent
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Women with > 3 months amenorrheaAutomated Self-Administered 24-hour Dietary Assessment Tool (ASA24)Women aged 18-40 years old with a diagnosis of functional hypothalamic amenorrhea, or lab results that are within the inclusion criteria.
Women with > 3 months amenorrheaREVEAL QuestionnaireWomen aged 18-40 years old with a diagnosis of functional hypothalamic amenorrhea, or lab results that are within the inclusion criteria.
Primary Outcome Measures
NameTimeMethod
Study Participants5 years

Establish and maintain a comprehensive registry of patients diagnosed with Functional Hypothalamic Amenorrhea (FHA). This registry will include detailed demographic information, clinical data, and longitudinal follow-up to track the prevalence, underlying causes, risk factors, and prognosis of FHA. It will also facilitate the collection of data on racial and ethnic disparities, lifestyle factors, psychological stressors, hormonal imbalances, and the impact of various treatment interventions on long-term health outcomes collected through questionnaires done at baseline and yearly.

Secondary Outcome Measures
NameTimeMethod
Assessing the Impact of Amenorrhea on Women's Health: Symptoms, Care Experiences, and Work Productivity5 years

Improve understanding of women's overall experience of Functional Hypothalamic Amenorrhea (FHA) by documenting the types of care received, frequency and quality of healthcare interactions, and patient satisfaction with the care provided. This includes detailed assessments of specific treatments or therapies received, the involvement of multidisciplinary care approaches, and the extent of follow-up care. Additionally, to quantify the impact of FHA on lost work productivity, including the number of workdays missed, impact on work performance, and economic burden associated with amenorrhea-related issues, measured at baseline and then yearly using questionnaires.

Impact of Social, Early Life, and Pregnancy Factors on Functional Hypothalamic Amenorrhea5 years

Enhance the understanding of how social determinants of health-such as socioeconomic status, education, access to healthcare, and community environment-contribute to the development of Functional Hypothalamic Amenorrhea (FHA). Additionally, the study will explore the impact of childhood adversity, including exposure to trauma, abuse, neglect, or chronic stress, on the likelihood of developing FHA. The relationship between pregnancy complications, such as preterm birth, miscarriage, or gestational conditions, and the onset of FHA will also be analyzed. Data will be collected through baseline and annual questionnaires throughout the study, providing a comprehensive understanding of these factors' roles in the development of FHA.

Trial Locations

Locations (1)

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath